Invivyd (NASDAQ:IVVD) Receives Buy Rating from D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Invivyd (NASDAQ:IVVD) in a research report sent to investors on Friday morning,Benzinga reports. D. Boral Capital currently has a $9.00 price objective on the stock.

IVVD has been the topic of a number of other reports. HC Wainwright dropped their target price on shares of Invivyd from $15.00 to $10.00 and set a “buy” rating on the stock in a research report on Wednesday, November 20th. EF Hutton Acquisition Co. I raised Invivyd to a “strong-buy” rating in a report on Wednesday, October 30th. Finally, Morgan Stanley reduced their target price on Invivyd from $9.50 to $3.55 and set an “overweight” rating for the company in a report on Wednesday, November 20th. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $7.89.

Invivyd Stock Down 2.1 %

Shares of Invivyd stock opened at $0.45 on Friday. Invivyd has a 52 week low of $0.40 and a 52 week high of $5.20. The firm’s 50 day moving average is $0.64 and its two-hundred day moving average is $0.91. The firm has a market capitalization of $54.07 million, a P/E ratio of -0.23 and a beta of 0.64.

Insiders Place Their Bets

In other Invivyd news, Director Terrance Mcguire sold 160,400 shares of Invivyd stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $0.59, for a total value of $94,636.00. Following the transaction, the director now directly owns 4,202,679 shares in the company, valued at approximately $2,479,580.61. This trade represents a 3.68 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In the last three months, insiders have sold 816,466 shares of company stock valued at $423,214. Insiders own 17.90% of the company’s stock.

Institutional Investors Weigh In On Invivyd

Several large investors have recently modified their holdings of the stock. Barclays PLC grew its position in Invivyd by 179.6% in the 3rd quarter. Barclays PLC now owns 117,973 shares of the company’s stock valued at $120,000 after buying an additional 75,780 shares during the last quarter. State Street Corp increased its stake in shares of Invivyd by 3.7% during the third quarter. State Street Corp now owns 1,018,640 shares of the company’s stock worth $1,039,000 after acquiring an additional 35,904 shares during the period. Proficio Capital Partners LLC purchased a new position in Invivyd during the third quarter worth about $27,000. Cubist Systematic Strategies LLC lifted its position in Invivyd by 66.1% in the second quarter. Cubist Systematic Strategies LLC now owns 134,452 shares of the company’s stock valued at $148,000 after purchasing an additional 53,499 shares during the period. Finally, Susquehanna Fundamental Investments LLC purchased a new stake in Invivyd in the 2nd quarter valued at approximately $115,000. Hedge funds and other institutional investors own 70.36% of the company’s stock.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.